Clariness announces the expansion of its new ClinLife Registry services to Poland and Austria in partnership with Boehringer Ingelheim RCV. The expansion follows years of patient enrolment support provided through Viomedo and then ClinLife®, following Clariness’ acquisition of Viomedo in 2018.
This partnership marks Boehringer Ingelheim as one of the first customers to expand its European patient recruitment through ClinLife. The expansion into Poland and Austria accelerate Boehringer Ingelheim’s patient enrolment across a number of indications, including mental illnesses such as borderline and depression.
“Transparency of clinical trials is very important to us at Boehringer Ingelheim. With Clariness, we have an experienced partner who helps us to jointly create transparency about ongoing clinical trials for patients in Poland and Austria,” says Hermann Novak, Regional Therapeutic Area Lead CNS, Retinopathies & Emerging Areas at Boehringer Ingelheim RCV.
Moritz Kloss, vice-president of ClinLife Registry at Clariness, added that “Expanding to new European markets with a partner like Boehringer Ingelheim shows that digital patient recruitment is essential to finding and matching patients with clinical trials moving forward.” Boehringer Ingelheim RCVs first clinical studies conducted in Poland and Austria are expected to go live on the ClinLife platform by the end of Q4 2021.
(Image licensed to Clariness from PopTika / Shutterstock)